Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE

Simple item page
dc.contributor.authorRomero, Roberto
dc.contributor.authorChaiworapongsa, Tinnakorn
dc.contributor.authorSavasan, Zeynep Alpay
dc.contributor.authorHussein, Youssef
dc.contributor.authorDong, Zhong
dc.contributor.authorPedro Kusanovic, Juan
dc.contributor.authorKim, Chong Jai
dc.contributor.authorHassan, Sonia S.
dc.date.accessioned2024-01-10T13:46:51Z
dc.date.available2024-01-10T13:46:51Z
dc.date.issued2012
dc.description.abstractObjective: High mobility group box-1 (HMGB1) protein is an alarmin, a normal cell constituent, which is released into the extracellular environment upon cellular stress/damage and capable of activating inflammation and tissue repair. The receptor for advanced glycation end products (RAGE) can bind HMGB1. RAGE, in turn, can induce the production of pro-inflammatory cytokines; this may be modulated by the soluble truncated forms of RAGE, including soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE). The objectives of this study were to determine whether: 1) clinical chorioamnionitis at term is associated with changes in amniotic fluid concentrations of HMGB1, sRAGE and esRAGE; and 2) the amniotic fluid concentration of HMGB1 changes with labor or as a function of gestational age. Methods: Amniotic fluid samples were collected from the following groups: 1) mid-trimester (n=45); 2) term with (n=48) and without labor (n=22) without intra-amniotic infection; and 3) term with clinical chorioamnionitis (n=46). Amniotic fluid concentrations of HMGB1, sRAGE and esRAGE concentrations were determined by ELISA. Results: 1) the median amniotic fluid HMGB1 concentration was higher in patients at term with clinical chorioamnionitis than in those without this condition (clinical chorioamnionitis: median 3.8 ng/mL vs. term in labor: median 1.8 ng/mL, p=0.007; and vs. term not in labor: median 1.1 ng/mL, p=0.003); 2) in contrast, patients with clinical chorioamnionitis had a lower median sRAGE concentration than those without this condition (clinical chorioamnionitis: median 9.3 ng/mL vs. term in labor: median 18.6 ng/mL, p=0.001; and vs. term not in labor median: 28.4 ng/mL, p<0.001); 3) amniotic fluid concentrations of esRAGE did not significantly change in patients with clinical chorioamnionitis at term (clinical chorioamnionitis: median 5.4 ng/mL vs. term in labor: median 6.1 ng/mL, p=0.9; and vs. term not in labor: median 9.5 ng/mL, p=0.06); and 4) there was no significant difference in the median AF HMGB1 concentration between women at term in labor and those not in labor (p=0.4) and between women in the mid-trimester and those at term not in labor (mid-trimester: median 1.5 ng/mL; p=0.2). Conclusion: An increase in the amniotic fluid HMGB1 concentration and a decrease in sRAGE were observed in clinical chorioamnionitis at term. This finding provides evidence that an alarmin, HMGB1, and one of its receptors, sRAGE, are engaged in the process of clinical chorioamnionitis at term. These changes are quite different from those observed in cases of intra-amniotic infection/inflammation in preterm gestations.
dc.description.funderPerinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
dc.fechaingreso.objetodigital2024-05-23
dc.format.extent10 páginas
dc.fuente.origenWOS
dc.identifier.doi10.3109/14767058.2011.599083
dc.identifier.eissn1476-4954
dc.identifier.issn1476-7058
dc.identifier.pubmedidMEDLINE:22578261
dc.identifier.urihttps://doi.org/10.3109/14767058.2011.599083
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79208
dc.identifier.wosidWOS:000304097600003
dc.information.autorucMedicina;Kusanovic J;S/I;1008900
dc.issue.numero6
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final567
dc.pagina.inicio558
dc.publisherTAYLOR & FRANCIS LTD
dc.revistaJOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
dc.rightsacceso restringido
dc.subjectdanger signal
dc.subjectintra-amniotic inflammation
dc.subjectsterile inflammation
dc.subjectpregnancy
dc.subjectneuroinflammation
dc.subjectneuro-immune reflex
dc.subjectamniotic fluid
dc.subjectDAMPs
dc.subjectdamage-associated molecular patterns
dc.subjectintra-amniotic infection
dc.subjectterm labor
dc.subjectGLYCATION END-PRODUCTS
dc.subjectMOBILITY GROUP BOX-1
dc.subjectPRETERM PREMATURE RUPTURE
dc.subjectTOLL-LIKE RECEPTORS
dc.subjectFACTOR-KAPPA-B
dc.subjectINFLAMMATORY CELL RECRUITMENT
dc.subjectAMNIOTIC-FLUID CONCENTRATIONS
dc.subjectHUMAN GESTATIONAL TISSUES
dc.subjectVEIN ENDOTHELIAL-CELLS
dc.subjectNUCLEAR-PROTEIN HMGB1
dc.subject.ods05 Gender Equality
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa05 Igualdad de género
dc.subject.odspa03 Salud y bienestar
dc.titleClinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE
dc.typeartículo
dc.volumen25
sipa.codpersvinculados1008900
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-23. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE.pdf
Size:
3.65 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas